PE20040169A1 - Derivados de quinazolin-4-amina como inhibidores de la transduccion de senal inducida por tirosinquinasas - Google Patents
Derivados de quinazolin-4-amina como inhibidores de la transduccion de senal inducida por tirosinquinasasInfo
- Publication number
- PE20040169A1 PE20040169A1 PE2003000322A PE2003000322A PE20040169A1 PE 20040169 A1 PE20040169 A1 PE 20040169A1 PE 2003000322 A PE2003000322 A PE 2003000322A PE 2003000322 A PE2003000322 A PE 2003000322A PE 20040169 A1 PE20040169 A1 PE 20040169A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- iloxi
- fluoro
- amino
- quinazoline
- Prior art date
Links
- 230000019491 signal transduction Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 title 1
- -1 1-PHENYLETHYL Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10214412A DE10214412A1 (de) | 2002-03-30 | 2002-03-30 | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE2002131711 DE10231711A1 (de) | 2002-07-13 | 2002-07-13 | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040169A1 true PE20040169A1 (es) | 2004-05-24 |
Family
ID=28676040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000322A PE20040169A1 (es) | 2002-03-30 | 2003-03-28 | Derivados de quinazolin-4-amina como inhibidores de la transduccion de senal inducida por tirosinquinasas |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1492536B1 (https=) |
| JP (1) | JP4776882B2 (https=) |
| KR (1) | KR101064530B1 (https=) |
| CN (1) | CN1642552B (https=) |
| AR (1) | AR039187A1 (https=) |
| AT (1) | ATE557008T1 (https=) |
| AU (1) | AU2003226705B2 (https=) |
| BR (1) | BR0308902A (https=) |
| CA (1) | CA2476008C (https=) |
| EA (2) | EA200701302A1 (https=) |
| HR (1) | HRP20040898A2 (https=) |
| IL (1) | IL164167A0 (https=) |
| ME (1) | MEP47208A (https=) |
| MX (1) | MXPA04009536A (https=) |
| MY (1) | MY127771A (https=) |
| NO (1) | NO329271B1 (https=) |
| NZ (1) | NZ536114A (https=) |
| PE (1) | PE20040169A1 (https=) |
| PL (1) | PL371188A1 (https=) |
| RS (1) | RS85404A (https=) |
| TW (2) | TW201024269A (https=) |
| UY (1) | UY27737A1 (https=) |
| WO (1) | WO2003082290A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE04748B1 (et) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP2280003B1 (en) * | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| CA2527017A1 (en) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| NZ544472A (en) | 2003-07-03 | 2009-04-30 | Myriad Genetics Inc | Compounds and therapeutical use thereof |
| DE10334226A1 (de) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| JP2007500177A (ja) * | 2003-07-29 | 2007-01-11 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体 |
| ES2305844T3 (es) * | 2003-09-16 | 2008-11-01 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de tirosina cinasa. |
| US20070032508A1 (en) * | 2003-09-16 | 2007-02-08 | Bradbury Robert H | Quinazoline derivatives as tyrosine kinase inhibitors |
| WO2005028469A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
| CN1882570B (zh) * | 2003-09-19 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| DE10345875A1 (de) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung |
| US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10350717A1 (de) * | 2003-10-30 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| ATE446750T1 (de) * | 2003-12-18 | 2009-11-15 | Janssen Pharmaceutica Nv | 3-cyano-chinolin-derivate mit antiproliferativer wirkung |
| UA83881C2 (en) | 2003-12-18 | 2008-08-26 | Янссен Фармацевтика Н.В. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
| JP5032851B2 (ja) | 2004-02-03 | 2012-09-26 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| EP1838712B8 (en) | 2004-12-14 | 2011-10-12 | AstraZeneca AB | Pyrazolopyrimidine compounds as antitumor agents |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| AU2006210175A1 (en) * | 2005-02-04 | 2006-08-10 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis |
| WO2006081741A1 (en) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Quinazoline compounds or their medical salts and preparation and medical usage thereof |
| MX2007010399A (es) * | 2005-02-26 | 2007-09-25 | Astrazeneca Ab | Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina. |
| CA2619037A1 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
| WO2007034144A1 (en) | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| BRPI0619603A2 (pt) * | 2005-12-12 | 2011-10-11 | Boehringer Ingelheim Int | heterociclos bicìclicos, sais fisiologicamante compatìveis, medicamentos que contêm esses compostos, bem como uso e processos para produção dos heterociclos bicìclicos |
| WO2007101782A1 (de) * | 2006-03-09 | 2007-09-13 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CA2654583C (en) | 2006-07-13 | 2015-11-24 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| CN101535279B (zh) * | 2006-09-11 | 2015-05-20 | 柯瑞斯公司 | 含锌结合基的喹唑啉基egfr抑制剂 |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| EP2118075A1 (de) * | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| EP1956010A1 (de) * | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel,deren Verwendung und Verfahren zu ihrer Herstellung |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| ES2562218T3 (es) | 2007-07-27 | 2016-03-03 | Janssen Pharmaceutica, N.V. | Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas |
| CA2711582A1 (en) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof |
| EP2303276B1 (en) * | 2008-05-13 | 2013-11-13 | AstraZeneca AB | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| EP2313398A1 (de) * | 2008-08-08 | 2011-04-27 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CA2733153C (en) * | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| JP5611207B2 (ja) * | 2008-08-08 | 2014-10-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式複素環の立体選択的調製方法 |
| CN101659657B (zh) * | 2008-08-29 | 2014-05-14 | 北大方正集团有限公司 | 氰基取代的喹啉衍生物及其制备方法和用途 |
| CN101659658B (zh) * | 2008-08-29 | 2014-04-02 | 北大方正集团有限公司 | 氰基取代的喹啉衍生物 |
| CA2735875A1 (en) * | 2008-09-03 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
| PL2451445T3 (pl) | 2009-07-06 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną |
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| UY33224A (es) * | 2010-02-15 | 2011-09-30 | Boehringer Ingelheim Int | Sales e hidratos de la 4-[(3-cloro-4-fluoro-fenil)amino]-6-(cis-4-{N-[(morf- 1 -olin-4-il)carbonil]-N-metil-amino}-ciclohexan-1-iloxi)-7-metoxi-quinazolina, uso y preparación |
| CN102452988B (zh) * | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | 一种喹唑啉衍生物及其制备方法 |
| EA023573B1 (ru) | 2011-02-01 | 2016-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| EA201400882A1 (ru) | 2012-02-09 | 2015-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях |
| WO2013143057A1 (zh) | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
| JP2015524400A (ja) | 2012-07-19 | 2015-08-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製 |
| KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| CN105209456B (zh) * | 2013-03-06 | 2018-05-08 | 阿斯利康(瑞典)有限公司 | 表皮生长因子受体的活化突变形式的喹唑啉抑制剂 |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
| EP4055014B1 (en) | 2019-11-06 | 2025-04-30 | Yuhan Corporation | PYRROLIDINE AND PIPERIDINE COMPOUNDS |
| CA3182410A1 (en) * | 2020-05-04 | 2021-11-11 | Volastra Therapeutics, Inc. | Imino sulfanone inhibitors of enpp1 |
| WO2025152954A1 (zh) * | 2024-01-15 | 2025-07-24 | 上海脉博实业有限公司 | 苯并嘧啶类化合物、其制备方法、药物组合物及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| DE10042058A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
-
2003
- 2003-03-25 CA CA2476008A patent/CA2476008C/en not_active Expired - Fee Related
- 2003-03-25 AU AU2003226705A patent/AU2003226705B2/en not_active Ceased
- 2003-03-25 JP JP2003579827A patent/JP4776882B2/ja not_active Expired - Fee Related
- 2003-03-25 WO PCT/EP2003/003062 patent/WO2003082290A1/de not_active Ceased
- 2003-03-25 HR HR20040898A patent/HRP20040898A2/hr not_active Application Discontinuation
- 2003-03-25 EP EP03745271A patent/EP1492536B1/de not_active Expired - Lifetime
- 2003-03-25 PL PL03371188A patent/PL371188A1/xx unknown
- 2003-03-25 NZ NZ536114A patent/NZ536114A/en not_active IP Right Cessation
- 2003-03-25 EA EA200701302A patent/EA200701302A1/ru unknown
- 2003-03-25 CN CN038072424A patent/CN1642552B/zh not_active Expired - Fee Related
- 2003-03-25 EA EA200401191A patent/EA009300B1/ru not_active IP Right Cessation
- 2003-03-25 AT AT03745271T patent/ATE557008T1/de active
- 2003-03-25 RS YUP-854/04A patent/RS85404A/sr unknown
- 2003-03-25 MX MXPA04009536A patent/MXPA04009536A/es active IP Right Grant
- 2003-03-25 ME MEP-472/08A patent/MEP47208A/xx unknown
- 2003-03-25 BR BR0308902-9A patent/BR0308902A/pt not_active IP Right Cessation
- 2003-03-25 IL IL16416703A patent/IL164167A0/xx not_active IP Right Cessation
- 2003-03-25 KR KR1020047015565A patent/KR101064530B1/ko not_active Expired - Fee Related
- 2003-03-27 UY UY27737A patent/UY27737A1/es not_active Application Discontinuation
- 2003-03-28 TW TW099102687A patent/TW201024269A/zh unknown
- 2003-03-28 AR ARP030101100A patent/AR039187A1/es unknown
- 2003-03-28 PE PE2003000322A patent/PE20040169A1/es not_active Application Discontinuation
- 2003-03-28 TW TW092107113A patent/TWI331604B/zh not_active IP Right Cessation
- 2003-03-28 MY MYPI20031160A patent/MY127771A/en unknown
-
2004
- 2004-09-23 NO NO20043997A patent/NO329271B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201024269A (en) | 2010-07-01 |
| HK1079095A1 (zh) | 2006-03-31 |
| HRP20040898A2 (en) | 2005-10-31 |
| TWI331604B (en) | 2010-10-11 |
| BR0308902A (pt) | 2005-01-04 |
| JP4776882B2 (ja) | 2011-09-21 |
| MEP47208A (en) | 2011-02-10 |
| NO329271B1 (no) | 2010-09-20 |
| EA009300B1 (ru) | 2007-12-28 |
| CA2476008C (en) | 2011-12-13 |
| PL371188A1 (en) | 2005-06-13 |
| EA200401191A1 (ru) | 2005-04-28 |
| KR101064530B1 (ko) | 2011-09-14 |
| NO20043997L (no) | 2004-10-27 |
| MXPA04009536A (es) | 2005-01-25 |
| CN1642552B (zh) | 2010-05-12 |
| IL164167A0 (en) | 2005-12-18 |
| CN1642552A (zh) | 2005-07-20 |
| AU2003226705A1 (en) | 2003-10-13 |
| RS85404A (sr) | 2007-02-05 |
| EP1492536A1 (de) | 2005-01-05 |
| KR20040094898A (ko) | 2004-11-10 |
| ATE557008T1 (de) | 2012-05-15 |
| UY27737A1 (es) | 2003-10-31 |
| TW200406211A (en) | 2004-05-01 |
| WO2003082290A1 (de) | 2003-10-09 |
| EA200701302A1 (ru) | 2007-12-28 |
| JP2005529090A (ja) | 2005-09-29 |
| AU2003226705B2 (en) | 2008-11-06 |
| AR039187A1 (es) | 2005-02-09 |
| EP1492536B1 (de) | 2012-05-09 |
| NZ536114A (en) | 2007-11-30 |
| CA2476008A1 (en) | 2003-10-09 |
| MY127771A (en) | 2006-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040169A1 (es) | Derivados de quinazolin-4-amina como inhibidores de la transduccion de senal inducida por tirosinquinasas | |
| UY25131A1 (es) | Derivados de ácidos ariloxiarilsulfonilamino hidroxamicos | |
| NO971342D0 (no) | Pyrrolo£2,3-d|pyrimidiner og deres anvendelse | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| ATE461179T1 (de) | Hemmer der akt aktivität | |
| EP1737843A4 (en) | HEMMER OF ACT ACTIVITY | |
| PA8501801A1 (es) | Inhibidores triciclicos de polimerasas (adp - polirribosas) | |
| PE20040953A1 (es) | Heterociclos biciclicos y procedimientos para su preparacion | |
| DE602004027490D1 (de) | Indazol-, benzisoxazol- und benzisothiazol-kinaseinhibitoren | |
| BRPI0412894A (pt) | tienopiridina e furopiridina inibidores de quinases | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| BR9814116A (pt) | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico | |
| PE20060524A1 (es) | Compuestos heterociclico fusionados como intermediarios en la preparacion de pirrolotriazinas inhibidoras de cinasa | |
| PE20060504A1 (es) | Derivados de pirimidina en el tratamiento de cancer | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| AR012660A1 (es) | Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon. | |
| PE20040400A1 (es) | Inhibidores de la transduccion de senales inducida por egfr relativos a hiperplasia prostatica benigna (hpb)/hipertrofia prostatica | |
| BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
| ATE384723T1 (de) | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs | |
| AR058286A1 (es) | Heterociclos biciclicos derivados de quinazolina 4-amino sustituidas, medicamentos que contienen estos compuestos, su utilizacion en el tratamiento de enfermedades mediadas por la actividad de las tirosinquinasas y las tiroquinasas y procedimientos para su preparacion | |
| ECSP045330A (es) | Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimiento para su preparación | |
| ATE424820T1 (de) | Verwendung von pyrrolederivaten gegen angstzustände | |
| ATE296633T1 (de) | Thiopyran-4-one als inhibitoren der dna protein kinase | |
| CY1105269T1 (el) | Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |